Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@jax.org
Therapy Name | Alvocidib + BAY-293 |
Synonyms | |
Therapy Description | |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
Alvocidib | flavopiridol|HMR 1275|L-868275|DSP-2033 | CDK Inhibitor (Pan) 3 CDK1 Inhibitor 13 CDK2 Inhibitor 30 CDK4 Inhibitor 17 CDK6 Inhibitor 6 CDK7 Inhibitor 16 CDK9 Inhibitor 21 | Alvocidib (flavopiridol) is an inhibitor of CDK1, CDK2, CDK4, CDK6, CDK7, and CDK9, which may induce cell cycle arrest and apoptosis in cancer cells (PMID: 12165651, PMID: 8674031, PMID: 24470357). | |
BAY-293 | BAY293|BAY 293 | SOS1 Inhibitor 14 | BAY-293 inhibits the interaction between Sos1 and Kras, leading to reduced Ras activation and downstream Erk phosphorylation, and potentially leading to decreased tumor cell proliferation (PMID: 30683722). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|